12/3
08:23 am
bcda
BioCardia Announces Election of New Board Director, Marvin Slosman and Completion of Term for Outgoing Director, Dr. Richard Krasno [Yahoo! Finance]
Medium
Report
BioCardia Announces Election of New Board Director, Marvin Slosman and Completion of Term for Outgoing Director, Dr. Richard Krasno [Yahoo! Finance]
12/3
08:00 am
bcda
BioCardia Announces Election of New Board Director, Marvin Slosman and Completion of Term for Outgoing Director, Dr. Richard Krasno
Medium
Report
BioCardia Announces Election of New Board Director, Marvin Slosman and Completion of Term for Outgoing Director, Dr. Richard Krasno
12/1
08:30 am
bcda
BioCardia to Present at December 2025 CSI Focus Devices in Heart Failure Congress
Low
Report
BioCardia to Present at December 2025 CSI Focus Devices in Heart Failure Congress
11/24
08:15 am
bcda
BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality
Low
Report
BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality
11/13
12:17 am
bcda
BioCardia, Inc. (BCDA) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Medium
Report
BioCardia, Inc. (BCDA) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/13
12:17 am
bcda
BioCardia anticipates Japan PMDA review and FDA meeting request on CardiAMP in Q4 2025 while advancing clinical programs [Seeking Alpha]
Medium
Report
BioCardia anticipates Japan PMDA review and FDA meeting request on CardiAMP in Q4 2025 while advancing clinical programs [Seeking Alpha]
11/12
04:40 pm
bcda
BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results
Medium
Report
BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results
11/10
08:30 am
bcda
BioCardia Announces Henry Ford Health Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial
Medium
Report
BioCardia Announces Henry Ford Health Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial
11/5
07:29 pm
bcda
BioCardia to Host Q3 2025 Corporate Update and Financial Results Conference Call on November 12, 2025
Low
Report
BioCardia to Host Q3 2025 Corporate Update and Financial Results Conference Call on November 12, 2025
11/1
01:04 am
bcda
Low
Report
10/30
08:00 am
bcda
BioCardia Announces University of Wisconsin Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial
Medium
Report
BioCardia Announces University of Wisconsin Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial
10/8
12:15 pm
bcda
BioCardia (NASDAQ:BCDA) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
BioCardia (NASDAQ:BCDA) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
10/2
09:15 am
bcda
BioCardia Regains Compliance with Nasdaq Listing Requirements [Yahoo! Finance]
Low
Report
BioCardia Regains Compliance with Nasdaq Listing Requirements [Yahoo! Finance]
10/2
08:25 am
bcda
BioCardia regains Nasdaq compliance after balance sheet improvements; shares up [Seeking Alpha]
Low
Report
BioCardia regains Nasdaq compliance after balance sheet improvements; shares up [Seeking Alpha]
10/2
08:00 am
bcda
BioCardia Regains Compliance with Nasdaq Listing Requirements
Low
Report
BioCardia Regains Compliance with Nasdaq Listing Requirements
9/25
07:39 am
bcda
BioCardia (NASDAQ:BCDA) was upgraded by analysts at Zacks Research to a "hold" rating.
Medium
Report
BioCardia (NASDAQ:BCDA) was upgraded by analysts at Zacks Research to a "hold" rating.
9/22
12:57 pm
bcda
BioCardia (NASDAQ:BCDA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
Low
Report
BioCardia (NASDAQ:BCDA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
9/22
08:00 am
bcda
BioCardia Announces Positive Preliminary Clinical Consultation with Japan Pharmaceutical and Medical Device Agency on Cell Therapy for Ischemic Heart Failure
Medium
Report
BioCardia Announces Positive Preliminary Clinical Consultation with Japan Pharmaceutical and Medical Device Agency on Cell Therapy for Ischemic Heart Failure
9/20
11:04 am
bcda
Bullish BioCardia Insider Buying Worth US$1.06m Yet To Pay Off [Yahoo! Finance]
Neutral
Report
Bullish BioCardia Insider Buying Worth US$1.06m Yet To Pay Off [Yahoo! Finance]